vs
Side-by-side financial comparison of INTEGRA LIFESCIENCES HOLDINGS CORP (IART) and Savers Value Village, Inc. (SVV). Click either name above to swap in a different company.
INTEGRA LIFESCIENCES HOLDINGS CORP is the larger business by last-quarter revenue ($434.9M vs $426.9M, roughly 1.0× Savers Value Village, Inc.). On growth, Savers Value Village, Inc. posted the faster year-over-year revenue change (8.1% vs -1.7%). INTEGRA LIFESCIENCES HOLDINGS CORP produced more free cash flow last quarter ($-5.4M vs $-6.3M). Over the past eight quarters, INTEGRA LIFESCIENCES HOLDINGS CORP's revenue compounded faster (8.6% CAGR vs 4.3%).
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.
Value Village Stores, Inc. was a Midwestern United States chain of retail stores aimed at the discount department-store market. Henry Horney, formerly of F.W. Woolworth Company founded a small, regional chain of discount stores located in the two states of Wisconsin and Illinois that opened in 1961 and operated into 1989. Horney also had a real estate company and often built small shopping malls adjoining the discount stores. The chain had no relation to the Savers Value Village chain of thri...
IART vs SVV — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $434.9M | $426.9M |
| Net Profit | — | $-14.0M |
| Gross Margin | 50.8% | — |
| Operating Margin | 5.3% | 8.5% |
| Net Margin | — | -3.3% |
| Revenue YoY | -1.7% | 8.1% |
| Net Profit YoY | — | -164.6% |
| EPS (diluted) | $-0.03 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $434.9M | — | ||
| Q3 25 | $402.1M | $426.9M | ||
| Q2 25 | $415.6M | $417.2M | ||
| Q1 25 | $382.7M | $370.1M | ||
| Q4 24 | $442.6M | $402.0M | ||
| Q3 24 | $380.8M | $394.8M | ||
| Q2 24 | $418.2M | $386.7M | ||
| Q1 24 | $368.9M | $354.2M |
| Q4 25 | — | — | ||
| Q3 25 | $-5.4M | $-14.0M | ||
| Q2 25 | $-484.1M | $18.9M | ||
| Q1 25 | $-25.3M | $-4.7M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | $-10.7M | $21.7M | ||
| Q2 24 | $-12.4M | $9.7M | ||
| Q1 24 | $-3.3M | $-467.0K |
| Q4 25 | 50.8% | — | ||
| Q3 25 | 51.5% | — | ||
| Q2 25 | 50.4% | — | ||
| Q1 25 | 50.8% | — | ||
| Q4 24 | 56.3% | — | ||
| Q3 24 | 52.6% | 25.6% | ||
| Q2 24 | 54.0% | 26.6% | ||
| Q1 24 | 56.1% | 24.2% |
| Q4 25 | 5.3% | — | ||
| Q3 25 | 2.9% | 8.5% | ||
| Q2 25 | -123.4% | 8.2% | ||
| Q1 25 | -4.0% | 2.8% | ||
| Q4 24 | 8.0% | 8.2% | ||
| Q3 24 | -2.1% | 12.3% | ||
| Q2 24 | -0.7% | 8.3% | ||
| Q1 24 | 1.1% | 4.6% |
| Q4 25 | — | — | ||
| Q3 25 | -1.3% | -3.3% | ||
| Q2 25 | -116.5% | 4.5% | ||
| Q1 25 | -6.6% | -1.3% | ||
| Q4 24 | — | -0.5% | ||
| Q3 24 | -2.8% | 5.5% | ||
| Q2 24 | -3.0% | 2.5% | ||
| Q1 24 | -0.9% | -0.1% |
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.07 | $-0.09 | ||
| Q2 25 | $-6.31 | $0.12 | ||
| Q1 25 | $-0.33 | $-0.03 | ||
| Q4 24 | $0.25 | $-0.02 | ||
| Q3 24 | $-0.14 | $0.13 | ||
| Q2 24 | $-0.16 | $0.06 | ||
| Q1 24 | $-0.04 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $263.7M | $63.5M |
| Total DebtLower is stronger | $726.6M | $750.0M |
| Stockholders' EquityBook value | $1.0B | $414.6M |
| Total Assets | $3.6B | $2.0B |
| Debt / EquityLower = less leverage | 0.70× | 1.81× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $263.7M | — | ||
| Q3 25 | $267.9M | $63.5M | ||
| Q2 25 | $253.6M | $70.5M | ||
| Q1 25 | $273.3M | $73.0M | ||
| Q4 24 | $273.6M | $150.0M | ||
| Q3 24 | $277.6M | $137.7M | ||
| Q2 24 | $296.9M | $160.7M | ||
| Q1 24 | $663.1M | $102.2M |
| Q4 25 | $726.6M | — | ||
| Q3 25 | $736.3M | $750.0M | ||
| Q2 25 | $745.9M | — | ||
| Q1 25 | $755.6M | — | ||
| Q4 24 | $760.5M | — | ||
| Q3 24 | $765.3M | — | ||
| Q2 24 | $770.2M | — | ||
| Q1 24 | $775.0M | — |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.0B | $414.6M | ||
| Q2 25 | $1.0B | $423.5M | ||
| Q1 25 | $1.5B | $413.8M | ||
| Q4 24 | $1.5B | $421.7M | ||
| Q3 24 | $1.5B | $432.9M | ||
| Q2 24 | $1.5B | $419.5M | ||
| Q1 24 | $1.6B | $395.0M |
| Q4 25 | $3.6B | — | ||
| Q3 25 | $3.6B | $2.0B | ||
| Q2 25 | $3.7B | $1.9B | ||
| Q1 25 | $4.1B | $1.9B | ||
| Q4 24 | $4.0B | $1.9B | ||
| Q3 24 | $4.1B | $1.9B | ||
| Q2 24 | $4.1B | $1.9B | ||
| Q1 24 | $4.1B | $1.8B |
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.71× | 1.81× | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.48× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.8M | $21.6M |
| Free Cash FlowOCF − Capex | $-5.4M | $-6.3M |
| FCF MarginFCF / Revenue | -1.2% | -1.5% |
| Capex IntensityCapex / Revenue | 4.0% | 6.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-31.1M | $25.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.8M | — | ||
| Q3 25 | $40.9M | $21.6M | ||
| Q2 25 | $8.9M | $54.4M | ||
| Q1 25 | $-11.3M | $419.0K | ||
| Q4 24 | $50.7M | $55.8M | ||
| Q3 24 | $22.5M | $23.9M | ||
| Q2 24 | $40.4M | $60.4M | ||
| Q1 24 | $15.8M | $-5.8M |
| Q4 25 | $-5.4M | — | ||
| Q3 25 | $25.8M | $-6.3M | ||
| Q2 25 | $-11.2M | $21.9M | ||
| Q1 25 | $-40.2M | $-20.2M | ||
| Q4 24 | $21.1M | $30.1M | ||
| Q3 24 | $-7.2M | $-3.0M | ||
| Q2 24 | $10.7M | $29.6M | ||
| Q1 24 | $291.0K | $-28.3M |
| Q4 25 | -1.2% | — | ||
| Q3 25 | 6.4% | -1.5% | ||
| Q2 25 | -2.7% | 5.2% | ||
| Q1 25 | -10.5% | -5.4% | ||
| Q4 24 | 4.8% | 7.5% | ||
| Q3 24 | -1.9% | -0.8% | ||
| Q2 24 | 2.6% | 7.6% | ||
| Q1 24 | 0.1% | -8.0% |
| Q4 25 | 4.0% | — | ||
| Q3 25 | 3.8% | 6.5% | ||
| Q2 25 | 4.8% | 7.8% | ||
| Q1 25 | 7.6% | 5.6% | ||
| Q4 24 | 6.7% | 6.4% | ||
| Q3 24 | 7.8% | 6.8% | ||
| Q2 24 | 7.1% | 8.0% | ||
| Q1 24 | 4.2% | 6.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.88× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.10× | ||
| Q2 24 | — | 6.22× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
SVV
| Sales Channel Directly To Consumer | $408.3M | 96% |
| Sales Channel Through Intermediary | $18.6M | 4% |
